2-(5-甲基-2-苯基-1,3-恶唑-4-基)-1-乙醇 | 103788-65-4

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 2-(5-甲基-2-苯基-1,3-恶唑-4-基)-1-乙醇
• 中文别名: 2-(5-甲基-2-苯基唑-1,3-二恶唑)-1-乙醇；2-(5-甲基-2-苯唑-4)乙醇；2-(5-甲基-2-苯基-1,3-恶唑-4-基)乙烷-1-醇；2-(5-甲基-2-苯基唑-1，3-二恶唑）-1-乙醇
• 英文名称: (5-methyl-2-phenyloxazol-4-yl)ethanol
• 英文别名: 2-(5-Methyl-2-phenyl-4-oxazolyl)ethanol；2-(5-Methyl-2-phenyl-1,3-oxazol-4-yl)ethan-1-ol；2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethanol
• CAS: 103788-65-4
• 化学式: C₁₂H₁₃NO₂
• mdl: MFCD00100006
• 分子量: 203.241
• InChiKey: JYWHQBLLIBQGCU-UHFFFAOYSA-N

物化性质

• 熔点：
  72 °C
• 沸点：
  365.4±34.0 °C(Predicted)
• 密度：
  1.146±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于氯仿（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  46.3
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 危险类别码：
  R36/37/38
• 海关编码：
  2934999090
• 安全说明：
  S22,S26,S36/37/39
• 储存条件：
  存储条件：2-8°C，密封，干燥。

SDS

Name:	2-(5-Methyl-2-phenyl-1 3-oxazol-4-yl)ethan-1-ol 97% Material Safety Data Sheet
Synonym:	None Known
CAS:	103788-65-4

Section 1 - Chemical Product MSDS Name:2-(5-Methyl-2-phenyl-1 3-oxazol-4-yl)ethan-1-ol 97% Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
103788-65-4	2-(5-Methyl-2-phenyl-1,3-oxazol-4-yl)e	97%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation. May cause chemical conjunctivitis.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Minimize dust generation and accumulation. Avoid breathing dust, vapor, mist, or gas. Avoid contact with eyes, skin, and clothing.
Keep container tightly closed. Avoid ingestion and inhalation. Use with adequate ventilation. Wash clothing before reuse.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 103788-65-4: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: cream
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 74 - 75 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C12H13NO2
Molecular Weight: 203

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable at room temperature in closed containers under normal storage and handling conditions.
Conditions to Avoid:
Dust generation.
Incompatibilities with Other Materials:
Bases, oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 103788-65-4 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
2-(5-Methyl-2-phenyl-1,3-oxazol-4-yl)ethan-1-ol - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
IMO
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
RID/ADR
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing group:

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 22 Do not breathe dust.
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
WGK (Water Danger/Protection)
CAS# 103788-65-4: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 103788-65-4 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 103788-65-4 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-(5-甲基-2-苯基-1,3-恶唑-4-基)-1-乙醇 在 lithium hydroxide 、 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 生成 法格立他扎
  参考文献：
  名称：

  N-（2-苯甲酰基苯基）-L-酪氨酸PPARγ激动剂。1.发现了一系列新型的有效降血糖药和降血脂药。

  摘要：

  我们已经鉴定出一系列新颖的抗糖尿病N-（2-苯甲酰基苯基）-L-酪氨酸衍生物，它们是有效的，选择性的PPARγ激动剂。通过使用体外PPARγ结合和功能测定（2S）-3-（4-（苄氧基）苯基）-2-（（1-甲基-3-氧代-3-苯基丙烯基）+ ++氨基o）丙酸（2）被确定为结构上新颖的PPARγ激动剂。结构-活性关系确定了2-氨基二苯甲酮部分是化合物2中化学不稳定的烯胺酮部分的合适等排体，提供了2-（（2-苯甲酰基苯基）氨基）-3-（4-（苄氧基）苯基）丙酸（9 ）。用噻唑烷二酮（TZD）类抗糖尿病药的体内已知取代基取代9中的苄基，可显着提高PPARgamma的体外功能效价和亲和力，提供一系列有效和选择性的PPARγ激动剂，例如（2S）-（（2-苯甲酰基苯基）氨基）-3-倒置问号4- [2-（甲基吡啶-2-基氨基+ ++）乙氧基]苯基倒置问号丙酸（ 18），3-倒置问号4- [2-（苯并恶唑-

  DOI：

  10.1021/jm9804127
• 作为产物：
  描述：

  2-（5-甲基-2-苯基1，3-氧杂醇-4-烷基）乙酸 在 dimethyl sulfide borane 作用下， 以 四氢呋喃 为溶剂， 以68%的产率得到2-(5-甲基-2-苯基-1,3-恶唑-4-基)-1-乙醇
  参考文献：
  名称：

  β-氧代-γ-苯基丁酸肟醚作为 PPAR α 和 -γ 双重激动剂的设计与合成

  摘要：

  在 PPAR α 和 γ 中分别为 2.5 nM 和 3.3 nM。在 db/db 小鼠模型中，它显示出比罗格列酮 1 更好的降糖作用，并改善了血浆甘油三酯等脂质分布。 (PPAR) 被归类为核受体家族的一个亚家族，并且已鉴定出三种同种型，即 PPAR α、-β/δ 和-γ。

  DOI：

  10.5012/bkcs.2012.33.6.1979
• 作为试剂：
  描述：

  2-(5-甲基-2-苯基-1,3-恶唑-4-基)-1-乙醇 、 甲基N-(2-苯甲酰基苯基)酪氨酸酯 在 2-(5-甲基-2-苯基-1,3-恶唑-4-基)-1-乙醇 作用下， 以70的产率得到(2S)-<(2-benzoylphenyl)amino>-3-<4-<2-(5-methyl-2-phenyloxazol4-yl)ethoxy>phenyl>propionic acid methyl ester
  参考文献：
  名称：

  Substituted 4-hydroxy-phenylalcanoic acid derivatives with agonist activity to PPAR-gamma

  摘要：

  化合物的化学式（I），其中A选自以下组中：（i）苯基，其中所述的苯基可选地被一个或多个卤原子，C1-6烷基，C1-3烷氧基，C1-3氟烷氧基，腈或—NR7R8取代，其中R7和R8独立地表示氢或C1-3烷基；（ii）含有至少一个来自氧，氮和硫的杂原子的5-或6成员杂环基团；以及（iii）融合的双环环（a），其中环C代表如上所定义的杂环基团（ii），该双环环通过环C的一个环原子连接到基团B上；B选自以下组中：（iv）C1-6烷基；（v）—MC1-6烷基或C1-6烷基MC1-6烷基，其中M为O，S或—NR2，其中R2表示氢或C1-3烷基；（vi）含有至少一个氮杂原子和可选地至少一个来自氧，氮和硫的进一步杂原子并且可选地被C1-3烷基取代的5-或6成员杂环基团；以及（vii）Het-C1-6烷基，其中Het代表如上所定义的杂环基团（vi）；Alk代表C1-3烷基；R1表示氢或C1-3烷基；Z选自以下组中：（viii）—（C1-3烷基）苯基，其中所述的苯基可选地被一个或多个卤原子取代；以及（ix）—NR3R4，其中R3表示氢或C1-3烷基，R4表示—Y—（C═O）—T—R5或—Y—（CH（OH））—T—R5。

  公开号：

  US06294580B1

文献信息

• <i>N</i>-(2-Benzoylphenyl)-<scp>l</scp>-tyrosine PPARγ Agonists. 3. Structure−Activity Relationship and Optimization of the <i>N</i>-Aryl Substituent
  作者：Jeff E. Cobb、Steven G. Blanchard、Evan G. Boswell、Kathleen K. Brown、Paul S. Charifson、Joel P. Cooper、Jon L. Collins、Milana Dezube、Brad R. Henke、Emily A. Hull-Ryde、Debra H. Lake、James M. Lenhard、William Oliver,、Jeffery Oplinger、Mila Pentti、Derek J. Parks、Kelli D. Plunket、Wei-Qin Tong

  DOI：10.1021/jm980414r

  日期：1998.12.1

  PPARgamma activity although binding affinity to PPARgamma may be maintained. A particularly promising set of analogues is the anthranilic acid esters 63-66 in which the phenyl ring in the 2-benzoyl group of 1 and 2 has been replaced by an alkoxy group. In particular, (S)-2-(1-carboxy-2- inverted question mark4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phen yl inverted question mark ethylamino)benzoic acid

  3-倒置问号4- [2-（苯并恶唑-2-基甲基氨基）乙氧基]苯基倒置问号-（2S）-（（2-苯甲酰基苯基）氨基）丙酸（1）和（2S）-（（2-苯甲酰基苯基）氨基）-3-反向问号4- [2-（5-甲基-2-苯基恶唑-4-基）e氧基]苯基反向问号丙酸（2）是过氧化物酶体增殖物激活受体γ（PPARgamma）激动剂，在2型糖尿病的啮齿动物模型中具有抗糖尿病活性。作为开发1和2的N-2-苯甲酰基苯基部分SAR的努力的一部分，从L-酪氨酸合成了一系列仅在N-2-苯甲酰基苯基部分修饰的新型羧酸类似物23-66。并被评估为PPARγ激动剂。通常，仅容许1和2的N-2-苯甲酰基苯基部分的适度变化。进一步来说，最好的变化涉及该部分两个苯环之一的生物立体取代。尽管可以维持对PPARγ的结合亲和力，但是向该部分添加取代基通常产生在PPARγ活性的基于细胞的功能测定中活性较低的化合物。一组特别有希望的类似物是邻氨
• Oxazole derivatives
  申请人：——

  公开号：US20030055265A1

  公开（公告）日：2003-03-20

  The present invention relates to novel oxazole compounds which act as PPAR&agr; and PPAR&ggr; agonists and are accordingly useful for the treatment of diseases modulated by PPAR&agr; and PPAR&ggr; such as diabetes.

  本发明涉及新型噁唑化合物，其作为PPAR&agr;和PPAR&ggr;激动剂，并因此可用于治疗由PPAR&agr;和PPAR&ggr;调节的疾病，如糖尿病。
• Enabling the Use of Alkyl Thianthrenium Salts in Cross‐Coupling Reactions by Copper Catalysis
  作者：Cheng Chen、Minyan Wang、Hongjian Lu、Binlin Zhao、Zhuangzhi Shi

  DOI：10.1002/anie.202109723

  日期：2021.9.27

  used groups in organic synthesis. Here, a a series of thianthrenium salts have been synthesized that act as reliable alkylation reagents and readily engage in copper-catalyzed Sonogashira reactions to build C(sp3)−C(sp) bonds under mild photochemical conditions. Diverse alkyl thianthrenium salts, including methyl and disubstituted thianthrenium salts, are employed with great functional breadth, since

  烷基是有机合成中应用最广泛的基团之一。在这里，已经合成了一系列的铪盐，它们作为可靠的烷基化试剂，可以很容易地参与铜催化的 Sonogashira 反应，在温和的光化学条件下建立 C(sp 3 )-C(sp) 键。由于敏感的 Cl、Br 和 I 原子在常规方法中耐受性差，因此可以使用多种烷基铪盐，包括甲基和双取代的铪盐，具有很大的功能广度。在铜催化的熊田反应中也证明了所开发的烷基试剂的通用性。
• Novel thiazolidine-2,4-diones as potent euglycemic agents.
  作者：Bernard Hulin、David A. Clark、Steven W. Goldstein、Ruth E. McDermott、Paul J. Dambek、Werner H. Kappeler、Charles H. Lamphere、Diana M. Lewis、James P. Rizzi

  DOI：10.1021/jm00088a022

  日期：1992.5

  A new series of thiazolidine-2,4-diones was obtained by replacing the ether function of englitazone with various functional groups, i.e., a ketone, alcohol, or olefin moiety. These compounds lower blood glucose levels in the genetically obese and insulin-resistant ob/ob mouse. Appending an oxazole-based group at the terminus of the chain provided highly potent compounds.

  通过用各种官能团即酮，醇或烯烃部分取代恩格列酮的醚官能团，获得了一系列新的噻唑烷-2,4-二酮。这些化合物可降低遗传性肥胖和胰岛素抵抗的ob / ob小鼠的血糖水平。在链的末端附加基于恶唑基的基团提供了高效的化合物。
• DPP IV inhibitors
  申请人：——

  公开号：US20030130281A1

  公开（公告）日：2003-07-10

  The present invention relates to compounds of formula (I) 1 wherein R 1 , R 2 , and X are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with DPP IV, such as diabetes, particularly non-insulin dependent diabetes mellitus, and impaired glucose tolerance.

  本发明涉及以下式（I）的化合物： 其中R1、R2和X如描述和权利要求中所定义，并且其药学上可接受的盐。这些化合物可用于治疗和/或预防与DPP IV相关的疾病，如糖尿病，特别是非胰岛素依赖型糖尿病和糖耐量受损。